Boehringer Ingelheim Vetmedica Launches Prascend®

Boehringer Ingelheim Vetmedica has launched Prascend®, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushings Disease. Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets. Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica, comments: “Many horses and ponies with Cushings Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future. “We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market.” For further information, visit www.prascend.co.uk or call 01344 746959.

More from

• Animus launches SkinBond Multi for enhanced wound care
• IVC Evidensia reports 82% cut in Farm antibiotic use and 20% carbon emissions reduction
• Vet professionals flock to sign up to transformative locum platform
• The ProSalus Foundation launches urgent appeal for UK vets to support Ukrainian colleagues
• Vetsure Named Business of the Year at 2025 SME National Business Awards